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Abstract 
We report the case of a 62-year-old woman with a history of vitreoretinal surgery for 
vitreous hemorrhage secondary to central retinal vein occlusion (CRVO). Because of the 
persistence of macular edema (ME), she received 2 intravitreal injections of bevacizumab 0.5 
mg (Avastin®, Genentech/Roche) three months after vitrectomy, without functional or 
anatomical improvement. Six months after vitrectomy, she therefore received an intravitreal 
implant of dexamethasone 0.7 mg (Ozurdex®). An improvement in her best-corrected visual 
acuity and central macular thickness, as measured by optical coherence tomography, was 
detected 7 days after the injection, and complete resolution of the ME and retinal 
hemorrhages was observed 6 months after the injection. Dexamethasone intravitreal 
implant might be an effective treatment option in ME secondary to CRVO, also in 
vitrectomized eyes. 
 
Introduction 
Macular edema (ME) is one of the main vision-threatening complications associated 
with central retinal vein occlusion (CRVO) [1]. In CRVO, increased intravascular  
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pressure and reduced blood flow in the macular capillaries can lead to dysfunction of 
the endothelial blood-retinal barrier and to increased vascular permeability, both of 
which result in ME [2]. 
Recently published clinical trials have shown that intravitreal dexamethasone 
(Ozurdex®; Allergan, Irvine, Calif., USA) and ranibizumab (Lucentis®; Novartis Pharma) 
are effective in the treatment of ME secondary to CRVO [3, 4]. Neither of these studies 
included eyes previously treated with vitrectomy. In vitrectomized eyes, ocular 
pharmacokinetics and pharmacodynamics are modified with an increase in the 
clearance of medications from the vitreous. It has been shown that the half-life of drugs 
after intravitreal injection is reduced in vitrectomized eyes [5]. This result was found 
after injection of anti-vascular endothelial growth factor (VEGF), used for the treatment 
of diabetic ME [6]. 
To address this drawback, a biodegradable dexamethasone drug delivery system 
was developed (Ozurdex). Ozurdex was designed to provide sustained delivery of 700 
mg of preservative-free dexamethasone to the vitreous cavity and retina for up to 180 
days [3]. In vitrectomized and nonvitrectomized rabbit eyes, it has been shown that 1 
month after implantation of the Ozurdex device, the concentration of dexamethasone in 
the vitreous cavity is similar [5]. 
We report a case of complete resolution of cystoid ME secondary to CRVO, refractory 
to previous treatments with intravitreal bevacizumab, with significant improvement of 
best-corrected visual acuity (BCVA), in a vitrectomized eye treated with an intravitreal 
implant of dexamethasone. 
Case Report 
A 62-year-old Caucasian woman presented at the University Eye Clinic at the Policlinico of Catania 
with a history of vitreoretinal surgery for vitreous hemorrhage in her right eye, secondary to CRVO. 
Because of the persistence of ME, three months after vitrectomy she received 2 intravitreal injections 
of bevacizumab 0.5 mg (Avastin®; Genentech/Roche), without functional or anatomical improvement 
after the injections. 
When the patient was first examined at our clinic, 6 months after vitrectomy, she was diagnosed 
with cystoid ME secondary to CRVO (fig. 1a). BCVA in the right eye was 1.2 logMAR and central foveal 
thickness was 672 μm as measured by SD-OCT (spectral domain optical coherence tomography; 
Spectralis, Heidelberg Engineering, Heidelberg, Germany) (fig. 2a). Therefore, she received an 
intravitreal implant of dexamethasone 0.7 mg (Ozurdex). 
An improvement in her BCVA to 0.9 logMAR was detected seven days after the injection; central 
macular thickness, measured by OCT and using the follow-up function, was 389 μm, with a reduction 
of 283 μm compared to the baseline value (fig. 2b). 
Six months after the injection of Ozurdex, complete resolution of the ME and retinal hemorrhages 
was observed (fig. 1b); central macular thickness was 203 μm and BCVA improved further to 0.6 
logMAR (fig. 2c). 
Discussion 
To our knowledge, there are no cases of intravitreal treatment of ME secondary to 
CRVO in vitrectomized eyes described so far in the literature. Recent studies have  
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evaluated the efficacy of the treatment of diabetic ME with intravitreal therapy in 
vitrectomized eyes: anti-VEGF failed to show a significant effect [6], while a prospective 
trial showed the efficacy of intravitreal Ozurdex implantation [7]. The results obtained 
in this latter study, as well as in our case, may have been caused by the favorable 
pharmacokinetics of a sustained-release dexamethasone implant. 
Interestingly, in this case, the treatment with dexamethasone was effective in one 
eye with chronic ME refractory to repeated anti-VEGF injections; one of the main 
mechanisms of chronic ME is the alteration of the functionality of Müller cells. It has 
been experimentally shown that steroids, by reducing the osmotic swelling of Müller 
cells, improve the functionality of these cells and reduce ME [8]. Therefore, the 
dexamethasone implant (Ozurdex) may lead to anatomical and functional improvement 
also in patients with ME due to retinal vein occlusion, even in long-standing cases [9]. 
Another finding in our patient was the long-term effect, namely the absence of 
edema for up to 6 months. After vitrectomy, when the vitreous gel is replaced with a 
less viscous saline solution, the transport of all molecules and oxygen is facilitated, 
leading to better oxygenation of the ischemic retinal areas [10]. 
In conclusion, the dexamethasone implant (Ozurdex) might be an effective treatment 
option in ME secondary to CRVO, also in vitrectomized eyes. 
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Fig. 1. a Fundus photography at baseline, before Ozurdex® injection, shows cystoid ME, widespread 
hemorrhaging and a swollen optic nerve in a vitrectomized eye. b Fundus photography 6 months after 
treatment shows a resolution of intraretinal hemorrhages and no ME. 
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Fig. 2. a Baseline Spectralis OCT, before Ozurdex® injection, shows cystoid ME, refractory to 2 
injections of Avastin®, in a vitrectomized eye; central retinal thickness was 672 μm. b Seven days 
after the injection of Ozurdex, using the follow-up function, OCT shows a 389-μm reduction in central 
retinal thickness. c Follow-up examination 180 days after Ozurdex injection. OCT shows the 
resolution of ME with a 469-μm reduction in central retinal thickness, compared to the baseline 
value. 
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